Dapivirine-Contraceptive Ring

Fast facts

  • Acts against: HIV-1; unintended pregnancy
  • Formulation: Silicone matrix vaginal ring
  • Active ingredient: Dapivirine (ARV); Levonorgestrel (contraceptive hormone) 
  • Length of action: Three months
  • Status: Phase I trial ongoing

Why is the dapivirine-contraceptive ring important?

Offering women a discreet, self-initiated, long-acting product could simultaneously protect them from two of the leading threats to their sexual and reproductive health and help encourage consistent use.

How does the dapivirine-contraceptive ring work? 

The ring is made of a flexible silicone matrix polymer and contains dapivirine, an ARV, and levonorgestrel, a contraceptive hormone, both of which are slowly released over the course of three months. 

Women insert the ring themselves into the vagina and replace it every three months.

What is its development history? 

Building on the ring technology used to develop the monthly dapivirine ring, IPM began developing the dapivirine-contraceptive ring in 2011 under a grant from the U.S. Agency for International Development through the President’s Emergency Plan for AIDS Relief. Early prototypes of a two-month multipurpose ring were developed in collaboration with Particle Sciences and Queens University Belfast. In 2014, after evaluating multiple materials and formulations, IPM and Queens University Belfast targeted a three-month silicone matrix ring.

What is its clinical history?

In April 2017, IPM and its clinical trial partner the Microbicide Trials Network, initiated MTN-030/IPM 041, a Phase I trial of the dapivirine-contraceptive ring. The trial is assessing the safety and pharmacokinetics of the three-month dapivirine-contraceptive ring, as well as a three-month dapivirine-only ring, in 24 healthy, HIV-negative women who are not pregnant in the United States. 

What are the next steps for the dapivirine-contraceptive ring?

MTN-030/IPM 041 began in April 2017. Results from the trial are expected in mid-2018 and will inform the next steps for the ring's formulation.

Who is IPM currently partnering with to develop and test the ring?

  • ARV license: Janssen Sciences Ireland UC for dapivirine 
  • Development: Queens University Belfast
  • Manufacturing: QPharma
  • Clinical trial: Microbicide Trials Network

Where can I learn more about multipurpose rings?